Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole in Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
NCT00171808Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Primary completion
- May 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letrozole in endometrial cancer (EC), sponsored by Novartis. Primary endpoint: Clinical Response Rate (PR + CR). Started Apr 2005; status: completed.
02
Drugs
letrozole
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00171808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171808.